A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma

NCT01302392 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

315

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Carfilzomib
DRUG: Best Supportive Care

Sponsor

Amgen